I noticed someone questioning MANF intellectual rights

New Post Public Reply Private Reply Replies (1) Message Board
KarinCA
I noticed someone questioning MANF intellectual rights elsewhere and thought I might as well post this here as well.
~~~~~~~~~~
Amarantus BioSciences Wins MANF Patent Challenge in Europe
http://www.amarantus.com/wp-content/uploads/2...ispute.pdf


Quote:
The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.



~~~~~~~~~~

10Q for period ended September 30, 2012

http://studio-5.financialcontent.com/edgar?ac...9412000844

From under table of contents on page 4:
Quote:
Overview

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. We focus on developing our intellectual property and proprietary technology to develop drug candidates to treat human disease. We own the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF”).

MANF is a protein that corrects protein misfolding. Protein misfolding is one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. Our lead MANF product development effort is centered on a therapy for Parkinson’s disease.

We also own an inventory of 88 cell lines that we refer to as PhenoGuard Cell Lines. MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. We believe that we may identify additional therapeutic proteins from its inventory of PhenoGuard Cell Lines.

Principal Products

Our philosophy is to acquire in-license, discover and develop biologics with the potential to address critically important biological pathways involved in human disease. Since our inception, we have been focused on developing MANF as a therapeutic for Parkinson’s disease, and other apoptosis-related disorders. Our business plans are focused in these specific areas:

- Development of MANF to treat Parkinson’s disease

- Development of MANF to treat other apoptosis-related disorders

- Exploration of our PhenoGuard Cell Lines for therapeutic protein discovery

- Evaluation of external drug candidates for potential in-licensure or acquisition

MANF: Overview

We own the intellectual property rights to a novel therapeutic protein called MANF acquired from EMS Development Group in 2008. MANF is a novel, endogenous, evolutionally conserved and widely expressed secreted human protein. We believe that MANF is the first of a new class of therapeutic proteins that are secreted in response to stressful physiological conditions in the body. MANF is believed to have mechanisms of action that are fundamentally different from other therapeutic proteins; MANF decreases the activity of apoptosis-causing enzymes, corrects protein misfolding and increases neurotransmitter release.



Search the SEC document and you'll find a lot about the company and MANF. Search under MANF

You'll even find how the rights were acquired.



Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Revenue Missteps Shake Semiconductor Stocks

Updated Category News Views 7

Nervous Times for Semiconductor Stocks When the semiconductor sector started October like a high-speed train, I thought we might sail through this month without hitting turbulence. But then, in trotted some shaky AI revenue numbers, and bam, the whole sector took a hit off its October highs. The semiconductor stocks, led by giants like Taiwan Semiconductor Manufacturing...

Continue Reading
Haag-Streit Debuts Innovative Octopus 910 Perimeter at AAO

Updated Category News Views 4

Now here's something that'll tickle your ophthalmologist's fancy—Haag-Streit USA has rolled out the Octopus 910, a slick piece of kit set to shake up visual field testing for glaucoma management. This time, they're getting in front of the competition, unveiling it at the Association for Research in Vision and Ophthalmology's 2026 shindig in New Orleans. With this new...

Continue Reading
NOARK: Powering Data Centers with Global-Local Approach

Updated Category News Views 6

The High-Stakes Race for Data Center Power These days, if you're not talking about data centers, you're probably a step behind the curve. AI's explosive growth is pushing data center developments across North America like never before. Larger campuses, hefty power densities—it's all happening at a pace that's got everyone scrambling. For folks like NOARK Electric, this...

Continue Reading
RingConn Smart Ring Gains Key FDA 510(k) Clearance

Updated Category News Views 11

FDA Clearance: A Major Step for RingConn In a space where every tiny gadget-maker is desperately clawing for a regulatory nod, RingConn—a venture born from Shenzhen Ninenovo Technology Limited—has snagged an FDA 510(k) clearance (Clearance No. K260490) for their wearable Smart Ring that measures blood oxygen levels non-invasively. October 10, 2026, marked the day when...

Continue Reading
AI in Music: CITY JAM Focuses on Human Creativity

Updated Category News Views 7

Breaking Down the AI Music Race In the wild world of music production, AI's making waves. Here's the thing though—it's all about how fast and how much it can churn out. Now, won't lie to you, that's impressive, but not the full picture. Pat Villaceran, the brain behind CITY JAM, is adamant that the real gold isn't just speed. It's the unique sound each artist brings to...

Continue Reading
Young Visionaries Win Junior Medals at STARMUS VIII

Updated Category News Views 10

Fresh from the Canary Islands' shores, STARMUS VIII has lifted the veil on two young powerhouses shaping tomorrow—Valeria Corrales and Aneeshwar Kunchala. These two have snagged coveted honors, crowning them as champions of their generation. Igniting Passion for Science and the Environment Valeria Corrales isn't just another face in the crowd; she’s the force behind a...

Continue Reading
Retail Trading Platforms Report Record Growth in 2026

Updated Category News Views 4

A Boom in Self-Directed Investing Times are changing, folks. More people than ever are taking finance into their own hands, wielding smartphones like fiscal swords in the name of self-directed investment. No middlemen, no fancy office, just straight-up trading from wherever you might be perched. Four major platforms now boast over 41 million funded accounts combined, each...

Continue Reading
KAPSARC Drives Energy Dialogue at WPC in Riyadh

Updated Category News Views 9

Defining Energy Horizons in Riyadh Mark those calendars, because as the global energy crowd descends on Riyadh from October 11 to 15, 2026, KAPSARC steps into the spotlight. As the National Partner at the 25th World Petroleum Congress (WPC), they're not just warming the bench—they're playing every position, shaking up the field of energy. Paving the Pathways with...

Continue Reading
Phoenix Scholar Examines AI and Institutional Trust

Updated Category News Views 7

A Thoughtful Look at Trust and Technology We're staring at an issue here that dives deep into the guts of how technology, AI in particular, is reshaping our professional landscape. The latest issue of the Phoenix Scholar, a publication from the University of Phoenix College of Doctoral Studies, is tackling big questions. It's that kind of brainy reading where you untangle...

Continue Reading
Kailas Campaign Binds Climbers with Gear, Trust

Updated Category News Views 5

Embracing the Spirit of Climbing Connections Alright, so when's the last time you saw a brand digging into the human side of one rugged sport like climbing? That's where Kailas steps in, pulling us beyond gear talk into the trust and camaraderie that defines climbing. Their latest effort—dubbed “Stay Warm, Stay Together”—goes beyond mere technical prowess by...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrate Mom with Epson's Creative Printing Solutions

Updated Category News Views 238

Making Mother's Day Special with Epson's EcoTank Printers Epson is paving the way for families to create memorable gifts this Mother's Day. With the EcoTank printers, crafting unique and heartfelt presents has never been easier. These printers offer a cartridge-free printing solution, allowing families to focus on their creative ideas without worrying about running out of...

Continue Reading
BioCity Biopharmaceutics Expands Cancer Treatment Options

Updated Category News Views 221

BioCity Biopharmaceutics Collaborates for Cancer Treatment BioCity Biopharmaceutics Co., Ltd., a forward-thinking biopharmaceutical company known for its innovative cancer treatment approaches, recently made a significant announcement regarding its clinical trial collaboration to explore the combination therapy of BC3195 and KEYTRUDA. This partnership aims to evaluate the...

Continue Reading
Navigating Early Retirement: Key Considerations for Investors

Updated Category News Views 228

Exploring the Impacts of Early Retirement Contemplating the possibility of leaving the workforce can be a formidable thought for many individuals. The allure of retiring early often clashes with the realities of financial planning and ongoing expenses. A 45-year-old individual recently reflected on this dilemma, questioning whether it was feasible to semi-retire or pivot...

Continue Reading
Understanding Wildfire Threats: A WTW and UEA Collaboration

Updated Category News Views 161

Understanding the Growing Wildfire Threat In light of recent environmental changes, it has become clear that wildfires are escalating into a significant global threat. Willis, a WTW business, recognized this challenge and has partnered with the University of East Anglia (UEA) to enhance our understanding of wildfire risks. As these events increasingly rival losses caused...

Continue Reading
Key Insights on AbbVie: Understanding Current Trends and Options

Updated Category News Views 152

Current Investors Sentiment Towards AbbVie Investors with substantial capital are showing a positive outlook on AbbVie (NYSE: ABBV), and this shift is something important players in the market should notice. Recent observations have gathered data indicating a considerable rise in options trading for AbbVie, hinting that significant changes might soon unfold. Unusual...

Continue Reading